/ALZCUR.ST
ALZCUR.ST Stock - AlzeCure Pharma AB (publ)
Healthcare|Drug Manufacturers - Specialty & GenericSTO
$2.08+1.46%
+$0.03 (+1.46%) • Dec 23
58
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.14
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.29
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALZCUR.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.06 – $2.10
TARGET (TP)$2.39
STOP LOSS$1.91
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.08
52W High$4.95
52W Low$0.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-293,000 | $-476,000 | $-570,000 | $-576,000 | $-495,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-36,454,000 | $-38,262,000 | $-56,442,000 | $-77,926,000 | $-71,579,000 |
| Net Income | $-35,234,000 | $-37,167,000 | $-56,036,000 | $-77,782,000 | $-71,367,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.46 | $-0.60 | $-1.18 | $-1.98 | $-1.82 |
Company Overview
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALZCUR.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.09
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Nov 11, 2025 | — | $-0.09 | — | — |
Q3 2025 | Aug 26, 2025 | — | $-0.10 | — | — |
Q2 2025 | May 5, 2025 | — | $-0.11 | — | — |
Q1 2025 | Feb 27, 2025 | — | $-0.11 | — | — |
Q4 2024 | Nov 11, 2024 | — | $-0.08 | — | — |
Q3 2024 | Aug 26, 2024 | — | $-0.12 | — | — |
Q2 2024 | Apr 25, 2024 | — | $-0.14 | — | — |
Q1 2024 | Feb 27, 2024 | — | $-0.16 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.12 | — | — |
Q3 2023 | Aug 24, 2023 | — | $-0.16 | — | — |
Q2 2023 | May 4, 2023 | — | $-0.15 | — | — |
Q1 2023 | Feb 24, 2023 | — | $-0.21 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.22 | — | — |
Q3 2022 | Aug 25, 2022 | — | $-0.42 | — | — |
Q2 2022 | May 5, 2022 | — | $-0.32 | — | — |
Q1 2022 | Feb 24, 2022 | — | $-0.51 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-0.43 | — | — |
Q3 2021 | Aug 25, 2021 | — | $-0.41 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ALZCUR.ST
What is ALZCUR.ST's current stock price?
AlzeCure Pharma AB (publ) (ALZCUR.ST) is currently trading at $2.08 per share. The stock has moved +1.46% today.
What is the analyst price target for ALZCUR.ST?
No analyst price targets are currently available for this stock.
What sector is AlzeCure Pharma AB (publ) in?
AlzeCure Pharma AB (publ) operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the STO exchange.
What is ALZCUR.ST's market cap?
AlzeCure Pharma AB (publ) has a market capitalization of $0.24 billion, making it a small-cap company.
Does ALZCUR.ST pay dividends?
No, AlzeCure Pharma AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACUC.ST
AcuCort AB
$0.57
Mkt Cap: $0.1B
BOUL.ST
Boule Diagnostics AB (publ)
$4.96
Mkt Cap: $0.2B
ERMA.ST
Enorama Pharma AB (publ)
$2.30
Mkt Cap: $0.2B
IRLAB-A.ST
IRLAB Therapeutics AB (publ)
$1.97
Mkt Cap: $0.2B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
KLAR.ST
Klaria Pharma Holding AB (publ.)
$0.61
Mkt Cap: $0.2B
LIPUM.ST
Lipum AB (publ)
$14.55
Mkt Cap: $0.3B
MNTC.ST
Mentice AB (publ)
$13.05
Mkt Cap: $0.4B
NANEXA.ST
Nanexa AB (publ)
$4.21
Mkt Cap: $0.7B
PTRK.ST
Physitrack PLC
$13.05
Mkt Cap: $0.2B
Explore stocks similar to ALZCUR.ST for comparison